EGFR and metastatic colorectal cancer: During the past 20 years, the adoption of monoclonal antibodies (mAbs) targeting the epithelial growth factor receptor (EGFR) has led to a dramatic improvement in the survival of metastatic colorectal cancer (mCRC) patients bearing RAS in its wild type isoform (RASwt).